Mississippi · Schedule I · ibogaine trials law enacted · tethered to a lead state
Mississippi did not go it alone — it bolted its trials onto another state's to skip the hardest step.
Mississippi's 2026 move is defined by what it does not have to build. The Legislature passed HB 314, signed by Gov. Tate Reeves on March 26 and effective July 1, directing the State Department of Health to form a research consortium — a drug developer, a lead university, and a hospital — to run ibogaine clinical trials aimed at FDA approval for opioid use disorder and neurological conditions such as PTSD. The distinctive part is structural: the law requires Mississippi to coordinate with, and use the same drug developer as, a lead consortium already operating in another state, the Texas-anchored ibogaine effort. As the bill's champion, Rep. Sam Creekmore (R), chair of the House Public Health and Human Services Committee, put it, partnering with a lead institution in another state meant Mississippi did not need its own complete FDA trial application. Funding is tied to roughly $5 million of the state's opioid-settlement money. Psilocybin itself stays Schedule I and illegal here.
90-second quick read · research companion
Need the full research version?
This is the 90-second cliff-note read on imicrodosing.net. For the cited deep-dive companion, read the full .org research page before moving into product decisions.
How the consortium is wired
A program tethered to another state's lead
Most state trials laws stand alone. Mississippi's is deliberately dependent: it attaches its in-state consortium to a lead institution in another state and shares that lead's drug developer, so the heaviest regulatory lifting happens elsewhere.
Mississippi engineered a shortcut. By coupling to a lead state's consortium and developer, it avoided having to file its own full FDA trial application.
Out-of-state lead institution
Texas-anchored ibogaine consortium
HB 314 requires Mississippi to coordinate with and use the same drug developer as a lead consortium already operating in another state, the Texas-anchored effort.
Shared with the lead state's consortium, so its FDA application carries the regulatory weight.
A Mississippi academic partner houses the study's research role.
An in-state hospital provides the clinical setting and cardiac monitoring.
Why opioid money
Settlement dollars aimed at addiction
The funding choice is its own story. Mississippi is steering about $5 million of its opioid-settlement money — the nonabatement portion lawmakers can direct to broader purposes — into ibogaine research, on the logic that the drug's most-studied use is breaking opioid dependence. That ties the program directly to the crisis the settlement money was meant to address.
Rep. Sam Creekmore, who chairs the House Public Health and Human Services Committee, drove the effort, hosting ibogaine advocates at the Capitol in August 2025 before the bill's 2026 passage. The measure cleared both chambers with bipartisan support, a notable outcome in a deep-red state, precisely because it was framed as addiction research funded by addiction-settlement dollars rather than as drug liberalization.
- Opioid-settlement funded — About $5M of nonabatement settlement money, via the AG budget.
- Addiction-first rationale — Ibogaine's most-studied use is opioid dependence.
- Bipartisan passage — Cleared both chambers in a deep-red state.
What it does and does not do
Ibogaine research, not psilocybin access
HB 314 is an ibogaine clinical-trials law. It does not decriminalize psilocybin, create a psilocybin program, or give the public any legal route to psychedelics. Psilocybin mushrooms, cultivation, and recreational possession all remain illegal in Mississippi.
For psilocybin, Mississippi's relevance is the model it pioneered: a small state can join the psychedelic-research wave cheaply by tethering to a larger consortium instead of building its own. If psilocybin programs ever spread the same way, the tethered structure Mississippi used for ibogaine is a template. For now, the only lawful psychedelic activity here would be inside the state-tied ibogaine trial.
3 cities
Where the consortium would actually sit
Jackson
UMMC academic anchor
~145K, the capital. Home to UMMC, the state's only academic medical center, and the Capitol where HB 314 passed.
Jackson pageGulfport
Gulf Coast + military
~72K, the largest Coast city. A casino-and-port economy and a heavy military footprint nearby give it a distinct veteran stake.
Gulfport pageHattiesburg
Pine Belt regional hub
~48K, the Pine Belt hub. The University of Southern Mississippi and Forrest General anchor a regional medical draw distinct from Jackson.
Hattiesburg pageCommon questions
Mississippi psilocybin FAQ
Q · 01
Is psilocybin legal in Mississippi?
No. Psilocybin is a Schedule I controlled substance in Mississippi and possession remains illegal. The 2026 law, HB 314, concerns ibogaine clinical trials and does not legalize or decriminalize psilocybin.
Q · 02
What is Mississippi HB 314?
It is a 2026 ibogaine clinical-trials law signed by Gov. Tate Reeves, effective July 1, 2026. It directs the State Department of Health to form a consortium of a drug developer, university, and hospital, coordinating with a lead consortium in another state, funded by about $5 million of opioid-settlement money.
Q · 03
Why is Mississippi tethered to another state?
The law requires Mississippi to use the same drug developer as a lead consortium in another state, the Texas-anchored effort. That coordination meant Mississippi did not need to file its own complete FDA trial application, making the program cheaper and faster to start.
Q · 04
Does HB 314 cover psilocybin?
No. The law is focused on ibogaine. It does not create any psilocybin access, and psilocybin stays Schedule I in Mississippi regardless of the ibogaine framework.
Q · 05
Can I get psychedelic therapy in Mississippi now?
No. There is no lawful psilocybin or ibogaine therapy available to the public. The only pathway the law creates is a future state-tied clinical trial, not an open clinic.
While Mississippi stands up its consortium
iMicrodosing.com ships lab-verified products within all applicable federal, state, and local laws. For deeper research and clinical context on psilocybin therapy outcomes, imicrodosing.org aggregates the trial literature.